Heart failure

Aug 17, 2018

Astellas’ Ophthalmology Innovation to Strengthen Further With Quethera Acquisition Astellas has acquired Quethera, a gene therapy company headquartered in the UK, which is focused on developing novel treatments for ocular disorders, such as glaucoma. Through this transaction, Astellas has acquired Quethera’s ...

Nov 04, 2016

According to National Society of Health, approximately 26 million patients are suffering from heart failure worldwide, with the increased economic burden of USD 30.7 billion each year. The advent of a novel class of drugs, i.e., the angiotensin receptor-neprilysin inhibitor, gives hope to the patients. Neprilysin is...